Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Unknown 2Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 26CNS 4Gastrointestinal 3Tumor-Agnostic 2Head & Neck 1

Conditions

Pancreatic Neoplasms 2Esophageal Neoplasms 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 216Irinotecan 185Cisplatin 143Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 41Cyclophosphamide 39trifluridine tipiracil drug combination 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × icotinib × Gastrointestinal × Clear all
NCT01855854 2019-07-05

Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH

Betta Pharmaceuticals Co., Ltd.

Phase 2 Completed
54 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT02024633 2015-07-15

Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 1 Unknown
24 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02278458 2015-05-22

Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 1 Unknown
24 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡